BioTuesdays
Ocugen

Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...

Allena Pharmaceuticals Logo

HCW starts Allena Pharma at buy; PT $10

H.C. Wainwright launched coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $10 price target. The stock closed at $1.68 on May 29. Allena is developing reloxaliase, an orally administered enzyme...

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

Mersana Therapeutics Logo

Analysts up Mersana Therapeutics PT to $21

Analysts for SVB Leerink and BTIG raised their price targets for Mersana Therapeutics (NASDAQ:MRSN) to $21 from $12 and $14, respectively, citing positive interim data from the expansion portion of the company’s Phase 1...

Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.